Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19.
Bogusz Jan Aksak-WąsDaniel ChoberKarol SerwinKaja ScheibeJolanta Niścigorska-OlsenAnna NiedźwiedźMonika DobrowolskaKatarzyna ŻybulMarta KubackaAgnieszka ZimońEwa HołdaJoanna Mieżyńska-KurtyczMarta GryczmanGrzegorz JamroPaweł SzakołaMiłosz ParczewskiPublished in: Journal of inflammation research (2022)
Remdesivir significantly reduced the early mortality rate in COVID-19 patients with comorbid hemato-oncological disease, which emphasizes the need to administer this agent to immunosuppressed patients.